Dr Donna Cosgrove PhD MPSI provides a clinical overview of analgesia and the many ways the pharmacist can help patients manage their pain

Good pain relief to a high proportion of people taking the medicine; 

Fast onset of action; and 

Long duration of action. 

‘Acute pain’, ie, pain lasting <12 weeks, can have many causes, often resulting from inflammation and swelling, which can significantly impact functional ability and quality of life.4 Self-care is encouraged for aches and pains, bruising, colds, cuts, earache, fever, headache, dysmenorrhoea, recovery after a simple medical procedure, self-limiting musculoskeletal pain, sinusitis/nasal congestion, sore throat, sprains and strains, teething, and toothache. However, patients are presented with such a very broad range of OTC analgesics, ie, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, complementary therapies, and herbal products, which can make medicine selection difficult.3 Even within these variations, different formulations are available: Fast-acting tablets, effervescent powders/tablets, liquids, and combination products. 

When a patient seeks pain relief, it is important to understand what outcome(s) the patient is seeking,3 ie:

Reduce pain intensity.

Improve physical functioning.

Aid return to work or school.

Improve health-related quality of life.

Over-the-counter analgesic drugs

NSAIDs mediate production of prostaglandins and thromboxane A2 through reversible inhibition of cyclo-oxygenase (COX). Prostaglandins mediate physiological functions, ie, inflammatory and nociceptive processes, maintaining the gastric mucosal barrier, and regulating renal blood flow and endothelial tone.4  Ibuprofen is the first-line recommendation for a range of aches and pains, including lower-back pain, period pain, and toothache.3 Aspirin is also used for aches and pains, such as headache, migraine, toothache and period pain, although ibuprofen tends to be preferred as it is better tolerated. NSAIDs should not be sold to patients with active gastrointestinal (GI) bleeding/ulcer; a history of hypersensitivity/severe allergic reaction, ie, asthma, rhinitis, angioedema or urticaria; severe heart failure; or severe kidney or liver impairment. Aspirin is contraindicated in history of hypersensitivity to aspirin or any other NSAID.

The mechanism of action of paracetamol has similarities to NSAIDs: It appears to inhibit COX 1 and COX 2, although it does not inhibit COX in peripheral tissues and, therefore, has no peripheral anti-inflammatory effects.5 Paracetamol metabolism is significantly influenced by genetics, which impacts toxicity and efficacy. Paracetamol is a suitable first-line choice for most adults with mild-to-moderate pain, based on the expert opinion of the Committee on the Safety of Medicines Pain Management Working Group,3 which includes members from the British Pain Society and the Medicines and Healthcare products Regulatory Agency (MHRA). It has no known GI, renal or cardiac adverse effects at usual OTC and prescribed doses.

Codeine metabolism is also subject to genetic influence. It is metabolised to morphine and morphine-6-glucuronide in the liver. Binding to central opioid receptors reduces pain perception and increases pain tolerance, but can also cause the unwanted effects of drowsiness and respiratory depression. Peripheral receptor binding can cause nausea, vomiting and constipation.4 

Evaluating efficacy of OTC analgesics

A Cochrane systematic review4 examined the relative efficacy of analgesic OTC drugs: Aspirin, paracetamol, and ibuprofen, both alone and in combinations with each other and with codeine/caffeine. Some products discussed in the review are not available OTC in Ireland (dipyrone, ibuprofen and caffeine combination products, ketoprofen, naproxen, and diclofenac). There was not enough information to establish the efficacy for several OTC analgesics, codeine plus aspirin/paracetamol; and combination products that include caffeine, which is reported to add to analgesic effects in acute pain when used as an additional drug at doses of 100mg or higher. 

Trials investigating analgesic efficacy in acute pain are usually performed in people experiencing postoperative pain (extraction of the third molar), with either the test analgesic or placebo administered. There are several measures of drug efficacy, including ‘Number needed to treat’ (NNT). The lower the NNT the better, with the ideal number NNT=1. This would be the case for an analgesic drug if every individual had good pain relief with the analgesic and no pain relief with placebo. Results of the Cochrane review indicate that the most favourable analgesics were combinations of ibuprofen and paracetamol (NNT<2). Fast-acting ibuprofen formulations (200 and 400mg) had an NNT close to 2 also. Another measure called the ‘success rate’ estimate is calculated from the number of people reporting effective analgesia, minus the number who report analgesia with placebo, expressed as a percentage of the maximum possible success rate for the analgesic. Ibuprofen-plus-paracetamol combination products had success rates of almost 70 per cent, and fast-acting ibuprofen formulations 200mg and 400mg showed success rates above 50 per cent. Paracetamol and aspirin at various doses had NNT values of 3 or above, and success rates of 11 per cent to 43 per cent. The rates of adverse drug events experienced for these medications were generally not different from placebo. Interestingly, for ibuprofen plus paracetamol, adverse drug events were lower than those recorded for placebo. 

Despite reported results, certain NICE guidelines recommend against using combination analgesics as first-line treatment because using single analgesics allows independent titration of each medicine. First-line treatment recommendations vary, depending on indication, and additional factors, ie, clinical presentation, suitability of treating OTC, patient comorbidities and contraindications, need to be considered. Treatment recommendations are summarised in Table 1.3

The cardiovascular risk associated with the use of NSAIDs has been of considerable interest.2 The large CNT (Coxib and traditional NSAID Trialists) concluded that using NSAIDs at high doses was associated with a small increased risk of all-cause mortality (20 per cent compared with placebo). However, the observation that people with chronic pain have increased rates of cardiovascular disease and a 20 per cent increased all-cause mortality in any event makes interpretation of these results tricky. Furthermore, the negative effect of chronic pain conditions on mobility separately increases mortality in chronic pain. 

Simple drug combinations and fast-acting formulations deliver good analgesia in many people with acute pain, at relatively low doses.3 If paracetamol is started at low dose, it can be increased to 1,000mg four times per day before switching to/combining with another analgesic. Ibuprofen 400mg three times per day is a low dose that can be increased to 2,400mg daily (although higher doses are recommended only on prescription). 

Although some patients may respond well to a given analgesic, others may respond poorly.3 It is important to be mindful that not every person will achieve good pain relief even with the most effective drugs, and analgesic failure is common when just a single dose is taken.6 It is likely that, if treatment with one OTC analgesic fails, an alternative may be beneficial. The underlying cause of the pain should be treated whenever possible, and a full therapeutic dose used before switching to a different analgesic. Pharmacy staff should initiate conversations with patients about what the patient has taken previously (if anything) and how they have taken it in order to advise appropriately. 

Pharmacy analgesic recommendations

A survey1 of 242 pharmacists was performed to explore recommendations, and efficacy and safety perceptions, of OTC analgesics. The authors report that recommendations were made primarily based on medication safety over efficacy, although observed perceptions of safety do not necessarily reflect existing evidence. This may potentially result in suboptimal outcomes of symptom resolution in acute pain. 

The most frequent recommendation for body pains and headache/migraine was paracetamol. While this falls in line with NICE guidance, other groups (British Association of Headache, the European Headache Federation and the European Federation for Neurological Societies (EFNS)) suggest that there is limited evidence for paracetamol efficacy in migraine, and that NSAIDs are more effective for tension headaches. The EFNS recommends ibuprofen 400mg for tension headaches instead.

The survey distributed among pharmacists indicates that paracetamol is perceived to be safer, better tolerated, and with fewer side-effects than ibuprofen for children. However, ibuprofen has been shown to provide faster, more effective, and longer-lasting relief for pyrexia: It has been reported that when used at an OTC dose for up to seven days in children, there was no significant statistical difference between ibuprofen and paracetamol in total rate of adverse events,7 with the rates at 13.7 per cent and 14.3 per cent, respectively. 

In adults, adverse events associated with ibuprofen occur more frequently at high prescription doses (>1,200mg daily) and when used for more extended periods of time.1 Although these adverse effects have not been linked to lower doses, the same adverse events seem nonetheless to be associated with them: While the survey showed that most pharmacists were aware of the safety of ibuprofen correlating with dose and duration, a high proportion did not believe there was a difference in tolerability between prescription and OTC doses. Although pharmacists perceive GI bleeding is a significant risk with ibuprofen at OTC doses, OTC dose ibuprofen (≤1,200mg) had a similar odds ratio (1.1) to paracetamol (2,000-3,999mg; OR 1.2) for GI bleeds. 

Indeed, paracetamol may not be without GI risk: A retrospective, longitudinal, cohort study of analgesic use in the UK found that paracetamol had an overall relative risk of upper GI events of 1.36; ibuprofen had an overall relative risk of 1.18. 

When pharmacists do recommend ibuprofen, we often recommend that patients take it with or after food, with the aim of minimising the perceived risk of GI adverse events. However, several trials have demonstrated similar rates of GI adverse events for ibuprofen vs placebo. In addition to this, taking analgesics with food significantly reduces absorption, in turn reducing efficacy, which potentially increases the likelihood or need for additional doses or alternative analgesics. In fact, many analgesia studies are likely to have been conducted in fasting participants, so results should be interpreted while taking this into consideration.4 Since publication of this review and following a review of clinical evidence by the MHRA, some patient information leaflets for ibuprofen have been updated to state that it needs to be taken with water, with no reference to taking it with food.5 The summary of product characteristics should be consulted regularly to check for such updates and to advise patients on correct administration.

When a patient seeks pain relief, it is important to understand what the desired outcome(s) are for the patient. Assessing the suitability of OTC analgesics given the clinical and medication history for everyone is key. Pharmacists and pharmacy staff can considerably improve treatment of pain through appropriate discussions and advice, and by basing treatment recommendations on guidelines supported by evidence.